LABORATORY CORPORATION OF AMERICA HOLDINGS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 198.4 USD | +0.03% |
|
-1.53% | -12.71% |
| Apr. 26 | Baird Adjusts Laboratory Corp of America Holdings' Price Target to $244 From $255 | MT |
| Apr. 26 | Barclays Adjusts Price Target on Laboratory Corp of America Holdings to $213 From $234 | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -12.71% | 16.73B | B | ||
| -14.92% | 84.68B | B- | ||
| +13.30% | 81.12B | C+ | ||
| +10.92% | 29.4B | C+ | ||
| -3.06% | 16.36B | A- | ||
| -2.63% | 14.92B | A- | ||
| -3.97% | 11.66B | A- | ||
| -1.42% | 11.72B | A- | ||
| -31.75% | 11.77B | - | - | |
| +27.44% | 11.71B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LH Stock
- Ratings Laboratory Corporation of America Holdings
